HC Wainwright Predicts Cytokinetics Q1 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Cytokinetics in a research report issued on Wednesday, February 25th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($1.57) per share for the quarter. HC Wainwright has a “Buy” rating and a $136.00 price target on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q2 2026 earnings at ($1.61) EPS and Q4 2026 earnings at ($1.89) EPS.

A number of other brokerages have also issued reports on CYTK. Truist Financial upped their price target on shares of Cytokinetics from $84.00 to $92.00 and gave the company a “buy” rating in a research note on Tuesday, February 3rd. Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a report on Monday, December 22nd. UBS Group reissued a “neutral” rating and issued a $61.00 target price on shares of Cytokinetics in a research report on Monday, December 1st. Citizens Jmp raised their target price on Cytokinetics from $88.00 to $96.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $90.00 price target on shares of Cytokinetics in a research note on Friday, January 9th. Sixteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $88.78.

Cytokinetics Stock Down 10.3%

Shares of Cytokinetics stock opened at $62.89 on Thursday. The firm has a market capitalization of $7.69 billion, a P/E ratio of -9.63 and a beta of 0.54. The company has a 50 day moving average price of $64.21 and a 200 day moving average price of $58.35. Cytokinetics has a 52 week low of $29.31 and a 52 week high of $70.98.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. During the same period in the previous year, the company posted ($1.26) earnings per share. The business’s quarterly revenue was up 4.9% on a year-over-year basis.

Institutional Investors Weigh In On Cytokinetics

Several hedge funds have recently bought and sold shares of CYTK. Woodline Partners LP grew its stake in shares of Cytokinetics by 676.1% during the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock worth $90,559,000 after purchasing an additional 1,435,422 shares during the period. Norges Bank purchased a new stake in Cytokinetics during the second quarter worth $39,122,000. Deep Track Capital LP grew its position in Cytokinetics by 17.8% during the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock valued at $236,328,000 after buying an additional 650,000 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in Cytokinetics by 151,987.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company’s stock valued at $35,949,000 after buying an additional 565,393 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. purchased a new position in Cytokinetics in the second quarter valued at $18,328,000.

Insider Buying and Selling at Cytokinetics

In other news, Director Wendell Wierenga sold 20,000 shares of the company’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $66.14, for a total value of $1,322,800.00. Following the sale, the director owned 32,444 shares in the company, valued at $2,145,846.16. This represents a 38.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Andrew Callos sold 15,000 shares of the firm’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $61.93, for a total value of $928,950.00. Following the sale, the executive vice president directly owned 50,440 shares in the company, valued at approximately $3,123,749.20. This trade represents a 22.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 151,385 shares of company stock valued at $9,817,158. 2.70% of the stock is owned by insiders.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: MYQORZO approved in U.S., China and Europe and U.S. launch is already underway; company reiterated 2026 catalysts (including ACACIA‑HCM topline in Q2) and disclosed substantial cash reserves. This is a material commercial and pipeline positive for future revenue. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised price targets and kept bullish ratings (Citizens JMP to $96 market‑outperform; Needham to $85 buy), signaling continued analyst conviction and upside vs. the current price. Benzinga coverage
• Positive Sentiment: Company highlighted a strong cash position (~$1.2B) to fund commercialization and upcoming trials — a balance‑sheet cushion that supports execution into 2026 catalysts. Zacks: CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
• Neutral Sentiment: Revenue beat estimates ($17.7M reported vs. ~$8M consensus), showing commercial pickup or other revenue sources, but revenue alone did not offset rising expenses this quarter. MarketBeat: Earnings details
• Neutral Sentiment: Full earnings call and transcripts are available for investors wanting details on expense drivers, launch timing and trial expectations. Seeking Alpha: Q4 2025 earnings call transcript InsiderMonkey transcript
• Negative Sentiment: EPS missed marginally ($‑1.50 vs. $‑1.48 expected) and the loss widened year‑over‑year as expenses rose, which likely triggered near‑term selling despite the revenue beat and approvals. Zacks: Q4 Loss, Beats Revenue Estimates

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.